Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Fuchs' endothelial dystrophy in which the cause of the disease is a mutation in the COL8A2 gene.
Features include: Corneal degeneration, Corneal stromal edema, Clouding of the cornea (corneal dystrophy), and Corneal guttata and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Corneal degeneration, Corneal stromal edema, Clouding of the cornea (corneal dystrophy) |
COL8A2 encodes collagen type VIII alpha 2 chain (703 aa). Macromolecular component of the subendothelium. Major component of the Descemet's membrane (basement membrane) of corneal endothelial cells. Also a component of the endothelia of blood vessels. Highest expression in Artery Aorta (77.2 TPM) and Artery Tibial (56.8 TPM).
Corneal dystrophy, Fuchs endothelial, 1 is associated with mutations in the COL8A2 gene on chromosome 1.
COL8A2 is classified as a druggable target (Druggable Genome category) with score 4.4.
Genetic testing for COL8A2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for corneal dystrophy, Fuchs endothelial, 1 has been reported in the published literature.
4 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and gene therapy. Pipeline includes 1 PHASE3, 1 PHASE2, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
29 publications have been identified in PubMed for corneal dystrophy, Fuchs endothelial, 1. Research spans Basic Science / Preclinical (41%), Review / Meta-Analysis (17%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 12 |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 1:06 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
41%
Research summaries | 5 | 17% |
Disease patterns and progression | 3 | 10% |
Other research | 2 | 7% |
Testing and diagnosis research | 2 | 7% |
Clinical study results | 2 | 7% |
New treatment approaches | 2 | 7% |
Patient case studies | 1 | 3% |
Yuan Y (2026). [PMID: 41840915](https://pubmed.ncbi.nlm.nih.gov/41840915/). *Genesis (New York, N.Y. : 2000)*. [Basic Science / Preclinical]
Jiang Y (2026). [PMID: 39778162](https://pubmed.ncbi.nlm.nih.gov/39778162/). *Cornea*. [Epidemiology / Natural History]
Zhou T (2026). [PMID: 41532702](https://pubmed.ncbi.nlm.nih.gov/41532702/). *Investigative ophthalmology & visual science*. [Basic Science / Preclinical]
Zhang W (2026). [PMID: 41896991](https://pubmed.ncbi.nlm.nih.gov/41896991/). *Biol Sex Differ*. [Basic Science / Preclinical]
Zhao X (2026). [PMID: 41575439](https://pubmed.ncbi.nlm.nih.gov/41575439/). *Investigative ophthalmology & visual science*. [Basic Science / Preclinical]
Zhang BN (2026). [PMID: 41850243](https://pubmed.ncbi.nlm.nih.gov/41850243/). *Cell reports. Medicine*. [Gene Therapy / Novel Therapeutics]
Landi E (2026). [PMID: 41285302](https://pubmed.ncbi.nlm.nih.gov/41285302/). *Progress in retinal and eye research*. [Review / Meta-Analysis]
Gurnani B (2026). [PMID: 31424832](https://pubmed.ncbi.nlm.nih.gov/31424832/). *Unknown Journal*. [Review / Meta-Analysis]
Zhao H (2026). [PMID: 42070230](https://pubmed.ncbi.nlm.nih.gov/42070230/). *Adv Sci (Weinh)*. [Gene Therapy / Novel Therapeutics]
Nayak D (2026). [PMID: 42061480](https://pubmed.ncbi.nlm.nih.gov/42061480/). *Free Radic Biol Med*. [Basic Science / Preclinical]